CN114605422A - 一对对映体生物碱二聚体类化合物及其制备方法和应用 - Google Patents
一对对映体生物碱二聚体类化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN114605422A CN114605422A CN202111334054.8A CN202111334054A CN114605422A CN 114605422 A CN114605422 A CN 114605422A CN 202111334054 A CN202111334054 A CN 202111334054A CN 114605422 A CN114605422 A CN 114605422A
- Authority
- CN
- China
- Prior art keywords
- compound
- fractions
- methanol
- dichloromethane
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 229930013930 alkaloid Natural products 0.000 title claims abstract description 25
- 239000000539 dimer Substances 0.000 title claims abstract description 21
- 150000003797 alkaloid derivatives Chemical class 0.000 title claims abstract description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 78
- 241000783421 Corydalis saxicola Species 0.000 claims abstract description 32
- 241000876833 Emberizinae Species 0.000 claims abstract description 32
- 239000012071 phase Substances 0.000 claims abstract description 29
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000003480 eluent Substances 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000010828 elution Methods 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 20
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 229920005654 Sephadex Polymers 0.000 claims abstract description 9
- 239000012507 Sephadex™ Substances 0.000 claims abstract description 9
- 239000007791 liquid phase Substances 0.000 claims abstract description 9
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims abstract description 8
- 238000003810 ethyl acetate extraction Methods 0.000 claims abstract description 8
- 239000000706 filtrate Substances 0.000 claims abstract description 8
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 8
- 235000002906 tartaric acid Nutrition 0.000 claims abstract description 8
- 239000011975 tartaric acid Substances 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 120
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 7
- 230000014759 maintenance of location Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000002024 ethyl acetate extract Substances 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000003208 petroleum Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000010829 isocratic elution Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002137 ultrasound extraction Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000012916 structural analysis Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 5
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 241000500915 Corydalus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003592 new natural product Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111334054.8A CN114605422B (zh) | 2021-11-11 | 2021-11-11 | 一对对映体生物碱二聚体类化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111334054.8A CN114605422B (zh) | 2021-11-11 | 2021-11-11 | 一对对映体生物碱二聚体类化合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114605422A true CN114605422A (zh) | 2022-06-10 |
CN114605422B CN114605422B (zh) | 2023-12-05 |
Family
ID=81857269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111334054.8A Active CN114605422B (zh) | 2021-11-11 | 2021-11-11 | 一对对映体生物碱二聚体类化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114605422B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115068474A (zh) * | 2022-07-14 | 2022-09-20 | 桂林医学院附属医院 | 脱氢卡维丁在制备治疗人肺腺癌药物组合物中的应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1706845A (zh) * | 2004-06-11 | 2005-12-14 | 林士煌 | 季胺白屈菜生物碱硫代磷酸衍生物 |
CN101028343A (zh) * | 2006-03-03 | 2007-09-05 | 上海医药工业研究院 | 一种岩黄连总生物碱及其纯化方法和药物组合物 |
CN101172975A (zh) * | 2006-11-03 | 2008-05-07 | 上海医药工业研究院 | 岩黄连五种生物碱组合物的制备方法 |
CN101428026A (zh) * | 2008-11-10 | 2009-05-13 | 成都军区昆明总医院 | 8-取代二氢苯并[c]菲啶类生物碱在制备抗耐药菌药物中的新用途 |
CN112979640A (zh) * | 2019-12-12 | 2021-06-18 | 中国医学科学院药物研究所 | 一类生物碱二聚体类化合物及其在制备pd-1/pd-l1通路抑制剂中的应用 |
-
2021
- 2021-11-11 CN CN202111334054.8A patent/CN114605422B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1706845A (zh) * | 2004-06-11 | 2005-12-14 | 林士煌 | 季胺白屈菜生物碱硫代磷酸衍生物 |
CN101028343A (zh) * | 2006-03-03 | 2007-09-05 | 上海医药工业研究院 | 一种岩黄连总生物碱及其纯化方法和药物组合物 |
CN101172975A (zh) * | 2006-11-03 | 2008-05-07 | 上海医药工业研究院 | 岩黄连五种生物碱组合物的制备方法 |
CN101428026A (zh) * | 2008-11-10 | 2009-05-13 | 成都军区昆明总医院 | 8-取代二氢苯并[c]菲啶类生物碱在制备抗耐药菌药物中的新用途 |
CN112979640A (zh) * | 2019-12-12 | 2021-06-18 | 中国医学科学院药物研究所 | 一类生物碱二聚体类化合物及其在制备pd-1/pd-l1通路抑制剂中的应用 |
Non-Patent Citations (2)
Title |
---|
CHUN-MEI SAI ET AL: "Two Pairs of Enantiomeric Alkaloid Dimers from Macleaya cordata", vol. 17, pages 4102 - 4105 * |
KAI LIU ET AL.: "Modular and Divergent Syntheses of Protoberberine and Protonitidine Alkaloids", vol. 23, pages 1327 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115068474A (zh) * | 2022-07-14 | 2022-09-20 | 桂林医学院附属医院 | 脱氢卡维丁在制备治疗人肺腺癌药物组合物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114605422B (zh) | 2023-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109897077B (zh) | 马齿苋中化合物Oleraciamide E及其提取分离方法与应用 | |
CN110272342A (zh) | 马齿苋中一种萘酸化合物及其提取分离方法与用途 | |
CN106008502A (zh) | 马齿苋中新骨架生物碱化合物及其提取分离方法 | |
CN114605422B (zh) | 一对对映体生物碱二聚体类化合物及其制备方法和应用 | |
CN112300104B (zh) | 马齿苋中一种木脂素类化合物及其提取分离方法和应用 | |
CN101899082A (zh) | 三萜皂苷类化合物、用途及制备方法 | |
CN105601693B (zh) | 人参皂苷f1的制备及其抗肿瘤作用 | |
CN102180850A (zh) | 一类麦冬中高异黄酮类化合物及制备方法和用途 | |
CN106083556A (zh) | 马齿苋中甘菊蓝结构新化合物及其提取分离方法 | |
CN102764320B (zh) | 山大颜提取物及其制备方法与抗肿瘤应用 | |
CN113278026B (zh) | 一种具有抗肿瘤活性的苦木素类化合物及其制备方法和应用 | |
CN111777657B (zh) | 一种皂苷化合物及其制备方法与应用 | |
CN109824685B (zh) | 马齿苋中化合物oleracone G及其提取分离方法与应用 | |
CN111377933B (zh) | 诸葛菜种子提取的生物碱类化合物及其提取方法与应用 | |
CN106810551A (zh) | 两种新碳架生物碱化合物及其提取分离方法 | |
CN108676054B (zh) | 一种三萜类化合物及其制备方法和应用 | |
CN115304611B (zh) | 两面针中两对二氢苯并菲啶生物碱类化合物及其提取方法和应用 | |
CN109206392B (zh) | 一种香豆素类化合物及其制备方法与应用 | |
CN107325069B (zh) | 一种倍半萜类化合物的提取方法 | |
CN105330588A (zh) | 马齿苋中新生物碱Oleracone及其提取分离方法 | |
CN106588853B (zh) | 一种含吡喃环酚类化合物及其制备方法和应用 | |
CN106045951B (zh) | 一种云实内酯及其制法和用途 | |
CN110294733A (zh) | 马齿苋中一种含过氧键化合物Oleracone I及其提取分离方法与应用 | |
CN115819411A (zh) | 两面针中7个木脂素类化合物及其提取方法和应用 | |
CN111675717B (zh) | 粉防己单体化合物及其提取方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20231110 Address after: 21-8, Building 1, No. 48 Tenglong Avenue, Tushan Town, Nan'an District, Chongqing, 400000 Applicant after: Fu Xunzhong Address before: 541004 No. 15 Yucai Road, Qixing District, Guilin, the Guangxi Zhuang Autonomous Region Applicant before: Guangxi Normal University |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231211 Address after: 610000 Tianfu International Biological City, Chengdu, Sichuan Province (No. 501, Building 4, No. 8 Huigu Road, Shuangliu District) Patentee after: Chengdu Yaoyilikang Pharmaceutical Technology Co.,Ltd. Address before: 21-8, Building 1, No. 48 Tenglong Avenue, Tushan Town, Nan'an District, Chongqing, 400000 Patentee before: Fu Xunzhong |
|
TR01 | Transfer of patent right |